ClinicalTrials.gg
CompletedNCT04909593AIMUpdated Dec 6, 2024Results posted

Study to Evaluate Automated Intensity Management in Patients Undergoing a BSC SCS Temporary Trial

An interventional study of Spinal Cord Stimulation in Chronic Pain, Intractable Pain and Low Back Pain, sponsored by Boston Scientific Corporation. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Boston Scientific Corporation · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to assess the feasibility of using information extracted from physiologic signals to automatically adjust stimulation in patients undergoing Spinal Cord Stimulation (SCS).

02

Conditions studied

  • Chronic Pain
  • Intractable Pain
  • Low Back Pain
  • Pain, Neuropathic
  • Pain, Back
03

In context

Chronic Pain

3,227 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.

This study's enrollment of 21 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.

Browse Chronic Pain studies →

Lead sponsor

Boston Scientific Corporation is the lead sponsor of 528 studies on the registry; 40 are open to participants now.

Of its 64 completed or terminated interventional studies of FDA-regulated products, 56 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Study candidate is undergoing a temporary SCS trial of commercially approved BSC neurostimulator system, per local directions for use (DFU).
  • Subject signed a valid, EC/IRB-approved form.
  • Age 18 or above, or above legal age and willing and capable of giving informed consent specific to national law when written informed consent is obtained.
  • In the clinician best judgment, subject is able to distinguishably describe quality and location of sensation and pain.

Key Exclusion Criteria:

  • Subject meets any in BSC neurostimulation system local DFU.
  • Investigator-suspected gross lead migration during the SCS trial period which may preclude the study candidate from receiving adequate SCS therapy.
  • Subject is currently diagnosed with cognitive impairment, or exhibits any characteristic, that in the clinician's best judgement would limit study candidate's ability to assess and report sensation information.
  • Subject is currently diagnosed with a physical impairment, or exhibits a condition that would limit study candidate's ability to complete study assessments.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Spinal Cord Stimulation

    SCS trial systems including external trial stimulators, lead(s)/extensions(s), and operating room (OR) cable(s)/extender(s) and optional sensor.

    Device: Spinal Cord Stimulation

Interventions

  • DeviceSpinal Cord Stimulation

    Spinal cord stimulation at varied electrode, pulse width, frequency and amplitude parameters

    Also known as: neurostimulation

06

What researchers measure

Primary outcomes

  1. Perception Threshold

    Percent change in patient's perceiving spinal cord stimulation (i.e. Perception Threshold) when going from a reclining to sitting position in a reclining chair

    Time frame: Programming Visit (up to 15 days post-screening)

07

Results

Posted Dec 6, 2024

Participant flow

Participant flow — Overall Study
MilestoneSpinal Cord Stimulation
Started21
Completed20
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPerception Threshold

Percent change in patient's perceiving spinal cord stimulation (i.e. Perception Threshold) when going from a reclining to sitting position in a reclining chair

Time frame:
Programming Visit (up to 15 days post-screening)
Reported as:
Mean · percent change in perception threshold
Perception Threshold
percent change in perception thresholdSpinal Cord Stimulation
Perception Threshold157 ± 52

Adverse events

Collected over From Informed consent through End of Study Visit (approximately 15 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Spinal Cord Stimulation0/21 (0%)0/21 (0%)0/21 (0%)

Baseline characteristics

All consented subjects

Age, Categorical
Age, Categorical(Participants)Spinal Cord Stimulation
<=18 years0
Between 18 and 65 years10
>=65 years11
Sex: Female, Male
Sex: Female, Male(Participants)Spinal Cord Stimulation
Female11
Male10
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Spinal Cord Stimulation
Caucasian17
Native American1
Black, of African Heritage2
American Indian or Alaska Native1
Region of Enrollment
Region of Enrollment(participants)Spinal Cord Stimulation
United States21
08

Study locations

1 site
  • PCPMG Clinical Research Unit, LLC
    Greenville, South Carolina 29601, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04909593
Responsible party
Sponsor
First posted
Jun 2, 2021
Start date
May 24, 2021
Primary completion
Nov 22, 2022
Completion
Nov 22, 2022
Results posted
Dec 6, 2024
Last update
Dec 6, 2024

Study contacts

Natalie Bloom Lyons
study director · Boston Scientific Neuromodulation Corporation

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion